Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 24, 2025
TOMI Secures $450,000 Contract for Custom Engineered System (CES) Installation
GlobeNewswire
·
March 24, 2025
FREDERICK, Md., March 24, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced a significant contract to install a SteraMist iHP …
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
GlobeNewswire
·
March 24, 2025
Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-up Successful vascularization and vessel formation in two-year follow-up 3D-printed resorbable scaffold to preserve both volume and …
Philips convenes the Annual General Meeting of Shareholders 2025
GlobeNewswire
·
March 24, 2025
March 24, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced it has convened the Annual General Meeting of Shareholders (AGM) 2025 and published the agenda with explanatory notes. As previously announced, the agenda …
Abivax Announces Full Year 2024 Financial Results
GlobeNewswire
·
March 24, 2025
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC …
Press Release: Availability of the Q1 2025 Aide mémoire
GlobeNewswire
·
March 24, 2025
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi …
Communiqué de presse : Mise en ligne du document « Q1 2025 Aide mémoire »
GlobeNewswire
·
March 24, 2025
Mise en ligne du document « Q1 2025 Aide mémoire » Paris, France, le 24 mars 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q1 2025 Aide mémoire ». Résultats du premier trimestre …
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
GlobeNewswire
·
March 24, 2025
Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H …
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de BLA du patch Viaskin® Peanut chez les enfants de 4-7 ans, accélérant ainsi au premier semestre 2026 le dépôt de la demande…
GlobeNewswire
·
March 24, 2025
Châtillon, France, le 24 mars (7h30 CEST) 2024 DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de licence de produit biologique (BLA) du patch Viaskin® Peanut chez les enfants de 4 à 7 ans, accélérant …
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
GlobeNewswire
·
March 24, 2025
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead …
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
GlobeNewswire
·
March 24, 2025
Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its …
Valneva répond à l'appel du gouvernement français pour la fourniture du vaccin IXCHIQ® contre l'épidémie de chikungunya à La Réunion
GlobeNewswire
·
March 24, 2025
Saint Herblain (France), le 24 mars 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’elle répondait avec son vaccin IXCHIQ® à l’épidémie de chikungunya qui s’intensifie rapidement sur l’ …
Santhera informiert am Capital Markets Day über den aktuellen Stand der kommerziellen Einführung von AGAMREE® und zukünftige strategische Prioritäten
GlobeNewswire
·
March 24, 2025
Pratteln, Schweiz, 24. März 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Unternehmen an seinem heutigen Capital Markets Day (CMD) in Zürich über die kommerziellen Fortschritte bei der weltweiten Markteinführung von AGAMREE® zur …
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
GlobeNewswire
·
March 24, 2025
Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of …
Opthea Announces COAST Phase 3 Trial Topline Results
GlobeNewswire
·
March 24, 2025
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and …
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
GlobeNewswire
·
March 24, 2025
SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
GlobeNewswire
·
March 24, 2025
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to …